Keith Williams Conclusion
I keep writing about Starpharma as I think it is a really interesting company that, being Australian, slips below the radar. It deserves more attention, albeit by risk-comfortable investors looking for substantial upside in a reasonably short time frame. While the company hasn't disclosed the milestone payment by Astra Zeneca for AZD0466 entering the clinic, I suspect it will be significant and support Starpharma's already strong cash position, which will help it fund the 3 other in-house DEP programs that are in clinical trials. Starpharma has foreshadowed that AZN0466 will enter clinical trials before the end of this calendar year. Perhaps that might also wake up interest in the company?
SPL Price at posting:
$1.22 Sentiment: Buy Disclosure: Held
